👤 Mengyang Li

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
3991
Articles
2551
Name variants
Also published as: Xiaofeng Li, Jingwen Li, Jiajia Li, Zhaolun Li, Litao Li, Ruyi Li, Xiaocun Li, Wanxin Li, Jianyu Li, Jinsong Li, Xinzhi Li, Guanqiao Li, Ying-Lan Li, Zequn Li, Yulin Li, Shaojian Li, Guang-Xi Li, Yubo Li, Bugao Li, Mohan Li, Yan-Xue Li, Qingchao Li, Xikun Li, Hong-Tao Li, Enhong Li, Guobin Li, Xiangnan Li, Yong-Jun Li, Ziming Li, Hang Li, Rongqing Li, Xihao Li, Jing-Ming Li, Chang-Da Li, Meng-Yue Li, Yuanchang Li, DaZhuang Li, Xiao-Lin Li, Yicun Li, Jiajie Li, Zhao-Yang Li, Shunqin Li, Xinjia Li, K-L Li, Yaqiong Li, Bin Li, Yuan-hao Li, Jianhai Li, Youran Li, Peiwu Li, Yongmei Li, Changyu Li, Ran Li, Peilin Li, X Y Li, Chunshan Li, Yixiang Li, Ming Zhou Li, Ye Li, Guanglve Li, Z Li, Zili Li, Xinmei Li, Yihao Li, Liling Li, Qing Run Li, Wulan Li, Meng-Yang Li, Ziyun Li, Haoxian Li, Xiaozhao Li, Jun-Ying Li, Da-Lei Li, Xinhai Li, Yongjiang Li, Wanru Li, Jinming Li, Huihui Li, Wenhao Li, Qiankun Li, Kailong Li, Shengxu Li, Shisheng Li, Sai Li, Guangwen Li, Hua Li, Xiuli Li, Dongmei Li, Yulong Li, Ru-Hao Li, Lanzhou Li, Zhi-Peng Li, Tingsong Li, Binjun Li, Chen Li, Yawei Li, Jiayang Li, Zunjiang Li, Chao Bo Li, Minglong Li, Donghua Li, Wenzhe Li, Siming Li, Fengli Li, Song Li, Zihan Li, Hsin-Hua Li, Jin-Long Li, Hongxin Li, Dongfeng Li, You Li, Xueyang Li, Xuelin Li, Fa-Hui Li, Caiyu Li, Zhen-Yuan Li, Guangpu Li, Teng Li, Wen-Jie Li, Hegen Li, Ang Li, Zhizong Li, Lu-Yun Li, Peng Li, Shiyu Li, Bao Li, Yin Li, Cai-Hong Li, Fang Li, Jiuke Li, Miyang Li, Chen-Xi Li, Mingxu Li, Panlong Li, Changwei Li, Dejun Li, Biyu Li, Yufeng Li, Miaoxin Li, San-Feng Li, Yaoqi Li, Hu Li, Bei Li, Sha Li, W H Li, Jiaming Li, Jiyuan Li, Ya-Qiang Li, Rongkai Li, Yani Li, Xiushen Li, Xiaoqing Li, Jinlin Li, Linke Li, C Y Li, Shuaicheng Li, Thomas Li, Siting Li, Xuebiao Li, Yingyi Li, Yongnan Li, Maolin Li, Jiyang Li, Jinchen Li, Jin-Ping Li, Xuewen Li, Zhongxuan Li, R Li, Xianlong Li, Aixin Li, Linting Li, Zhong-Xin Li, Xuening Li, Enhao Li, Guang Li, Xiaoming Li, Shengliang Li, Yongli Li, Z-H Li, Baohong Li, Hujie Li, Yue-Ming Li, Shuyuan Li, Zhaohan Li, L Li, Yuanmei Li, Alexander Li, Yanwu Li, Hualing Li, Wen-juan Li, Sibing Li, Qinghe Li, Xining Li, Pilong Li, Yun-Peng Li, Zonghua Li, C X Li, Jingya Li, Huanan Li, Liqin Li, Youjun Li, Zheng-Dao Li, Miao X Li, Zhenshu Li, KeZhong Li, Heng-Zhen Li, Linying Li, Chu-Qiao Li, Fa-Hong Li, Changzheng Li, Yuhui Li, Wei Li, Wen-Ying Li, Yaokun Li, Shuanglong Li, Zhi-Gang Li, Yufan Li, Liangqian Li, Guanghui Li, Xiongfeng Li, Fei-feng Li, Letai Li, Ming Li, Kangli Li, Runwen Li, Wenbo Li, Yarong Li, Side Li, Weidong Li, S E Li, Timmy Li, Xin-Tao Li, Ruotong Li, Xiuzhen Li, Shuguang Li, Chuan-Hai Li, Lingxi Li, Qiuya Li, Jiezhen Li, Haitao Li, Tingting Li, Guanghua Li, Yufen Li, Zhongyu Li, Qin Li, Deyu Li, Zhen-Yu Li, Hansen Li, Annie Li, Wenge Li, Jinzhi Li, Xueren Li, Chun-Mei Li, Yijing Li, Kaifeng Li, Wen-Xing Li, Meng-Yao Li, Chung-I Li, Zhi-Bin Li, Xiao Li, Qintong Li, Junping Li, PeiQi Li, Naishi Li, Xiaobing Li, Liangdong Li, Xin-Ping Li, Yan Li, Han-Ni Li, Pan Li, Shengchao A Li, Jiaying Li, Jun-Jie Li, Cui-lan Li, Ruonan Li, Shuhao Li, Ruitong Li, Huiqiong Li, Guigang Li, Lucia M Li, Chunzhu Li, Suyan Li, Chengquan Li, Zexu Li, Gen-Lin Li, Dianjie Li, Zhilei Li, Junhui Li, Tiantian Li, Xue Cheng Li, Ya-Jun Li, Wenyong Li, Ding-Biao Li, Tianjun Li, Desen Li, Yansong Li, Xiying Li, Zihao Li, Weiyong Li, Xinyang Li, Fadi Li, Huawei Li, Yu-quan Li, Cui Li, Xiaoyong Li, Y L Li, Xueyi Li, Jingxiang Li, Wenxue Li, Jihua Li, Jingping Li, Zhiquan Li, Zeyu Li, Yingpu Li, Jianglin Li, Jing-Yao Li, Yan-Hua Li, Zongdi Li, Ming V Li, Shawn Shun-Cheng Li, Aowen Li, Xiao-Min Li, L K Li, Ya-Ting Li, Wan Jie Li, Aimin Li, Dongbiao Li, Tiehua Li, Keguo Li, Yuanfei Li, Longhui Li, Jing-Yi Li, Zhonghua Li, Guohong Li, Chunyi Li, Botao Li, Peiyun Li, Xiuqi Li, L-Y Li, Qinglan Li, Zhenhua Li, Zhengda Li, Haotong Li, Yue-Ting Li, Luhan Li, Da Li, Yuancong Li, Yuxiu Li, Tian Li, YiPing Li, Beibei Li, Haipeng Li, Demin Li, Chuan Li, Changhong Li, Ze-An Li, Jianmin Li, Yu Li, Minhui Li, Yvonne Li, Yiwei Li, Jiayuan Li, Xiangzhe Li, Zhichao Li, Minglun Li, Yige Li, Siguang Li, Chengqian Li, Weiye Li, Xue-Min Li, Kenneth Kai Wang Li, Dong-fei Li, Xiangchun Li, Chiyang Li, Chunlan Li, Hulun Li, Juan-Juan Li, Hua-Zhong Li, Hailong Li, Kun-Peng Li, Jiaomei Li, Haijun Li, Jing Li, Si Li, Xiangyun Li, Ji-Feng Li, Yingshuo Li, Wanqian Li, Baixing Li, Zijing Li, Dengke Li, Yuchuan Li, Wentao Li, Qingling Li, Rui-Han Li, Xuhong Li, Dong Li, Hongyun Li, Zhonggen Li, Xiong Li, Penghui Li, Xiaoxia Li, Dezhi Li, Huiting Li, Xiaolong Li, Linqing Li, Jiawei Li, Sheng-Jie Li, Defa Li, Ying-Qing Li, X L Li, Yuyan Li, Kawah Li, Xin-Jian Li, Guangxi Li, Yanhui Li, Zhenfei Li, Shupeng Li, Sha-Sha Li, Panyuan Li, Gang Li, Mengxuan Li, Ziyu Li, Hong-Wen Li, Zhuo Li, Han-Wei Li, Weina Li, Xiaojuan Li, Xiao-Hui Li, Huaiyuan Li, Dongnan Li, Rui-Fang Li, Jianzhong Li, Ji-Liang Li, Huaping Li, C H Li, Bohua Li, Bing Li, Pei-Ying Li, Huihuang Li, Shaobin Li, Yunmin Li, Yanying Li, Ronald Li, Gui Lin Li, Chenrui Li, Shi-Hong Li, Shilun Li, John Zhong Li, Xinyu Li, Song-Chao Li, Lujiao Li, Chenghong Li, Dengfeng Li, Nianfu Li, Baohua Li, N Li, Xiaotong Li, Chensheng Li, Ming-Qing Li, Yongxue Li, Bao-Shan Li, Jiao Li, Zhimei Li, Jun-Cheng Li, Yimeng Li, Jingming Li, Jinxia Li, De-Tao Li, Chunting Li, Shu Li, Julia Li, Chien-Feng Li, Huilan Li, Mei-Zhen Li, Xin-Ya Li, Zhengjie Li, Chunsheng Li, Yan-Yan Li, Liwei Li, Huijun Li, Chengyun Li, Chengjian Li, Ying-na Li, Guihua Li, Zhiyuan Li, Lijun Li, Supeng Li, Hening Li, Yiju Li, Yuanhe Li, Fengxia Li, Guangxiao Li, Peixin Li, Xueqin Li, Feng-Feng Li, Zu-Ling Li, Jialing Li, Yunjiu Li, Xin Li, Dayong Li, Zonghong Li, Ningyan Li, Lingjiang Li, Yuhan Li, Zhenghui Li, Fuyuan Li, Ailing Li, H-F Li, Chunxia Li, Chaochen Li, Zhen-Li Li, Tengyan Li, Xianlu Li, Jiaqi Li, Jiabei Li, Zhengying Li, Yali Li, Zhaoshui Li, Wenjing Li, Yu-Hui Li, Jingshu Li, Chuang Li, Jiajun Li, Can Li, Zhe Li, Han-Bo Li, Stephen Li, Shuangding Li, Zengyang Li, Kaiyuan Li, Mangmang Li, Chunyan Li, Runzhen Li, Xiaopeng Li, Xi-Hai Li, Xuezhong Li, Anan Li, MengGe Li, Luying Li, Jiajv Li, Pei-Lin Li, Xiaoquan Li, Ning Li, Ruobing Li, Yanxi Li, Wan-Xin Li, Yongjing Li, Xia Li, Meitao Li, Huayao Li, Ziqiang Li, Wen-Xi Li, Shenghao Li, Boxuan Li, Jiqing Li, Huixue Li, Hehua Li, Yucheng Li, Qingyuan Li, Yongqi Li, Fengqi Li, Zhigang Li, Yuqing Li, Guiyang Li, Guo-Qiang Li, Dujuan Li, Yanbo Li, Yuying Li, Shaofei Li, Sanqiang Li, Shaoguang Li, Hongyu Li, Min-Rui Li, Guangping Li, Shuqiang Li, Dan C Li, Huashun Li, Jinxin Li, Ganggang Li, Xinrong Li, Haoqi Li, Yayu Li, Handong Li, Huaixing Li, Yan-Nan Li, Xianglong Li, Minyue Li, Hong-Mei Li, Jing-Jing Li, Songhan Li, Jutang Li, Mengxia Li, Conglin Li, Qingli Li, Yongxiang Li, Miao Li, Songlin Li, Qilong Li, Dijie Li, Chenyu Li, Yizhe Li, Ke Li, Yan Bing Li, Jiani Li, Lianjian Li, Zhen-Hua Li, Yiliang Li, Chuan-Yun Li, Xinpeng Li, Hongxing Li, Wanyi Li, Gaoyuan Li, Youming Li, Mi Li, Qingrun Li, Dong-Yun Li, Guo Li, Jingxia Li, Xiu-Ling Li, Fuhai Li, Ruijia Li, Shuangfei Li, Yumiao Li, Fengfeng Li, Qinggang Li, Jiexi Li, Huixia Li, Kecheng Li, Xiangjun Li, Junxu Li, Xingye Li, Junya Li, Jiang Li, Huiying Li, Shengxian Li, Yuxi Li, Qingyang Li, Chenxuan Li, Xiao-Dong Li, Xinghuan Li, Zhaoping Li, Xingyu Li, Zhenlu Li, Xiaolei Li, Wenying Li, Huilong Li, Xiao-Gang Li, Honghui Li, Zhenhui Li, Cheung Li, Zhenming Li, Xuelian Li, Shu-Fen Li, Chunjun Li, Changyan Li, Mulin Jun Li, Yinghua Li, Shangjia Li, Yanjie Li, Jingjing Li, Suhong Li, Xinping Li, Siyu Li, Chaoying Li, Qiu Li, Juanjuan Li, Guangzhen Li, Xiangyan Li, Kunlun Li, Xiaoyu Li, Shiyun Li, Yaobo Li, Shiquan Li, Xuewang Li, Mei Li, Xiangdong Li, Jifang Li, Zhenjia Li, Wan Li, Manjiang Li, Zhizhong Li, Ding Yang Li, Xiaoya Li, Xiao-Li Li, Shan Li, Shitao Li, Lijia Li, Zehan Li, Huiliang Li, Chunqiong Li, Junjun Li, Chenlong Li, Shujin Li, Hui-Long Li, Zhao-Cong Li, Zhi-Wei Li, Weining Li, Wenxi Li, Wu-Jun Li, Chang-hai Li, Yumao Li, Bin-Kui Li, Yuqiu Li, Honglian Li, Xue-Yan Li, Ya-Zhou Li, Yuan-Yuan Li, Xiang-Jun Li, Hongyi Li, Chia Li, Y X Li, Yunyun Li, Zhen-Jia Li, Fu-Rong Li, Honghua Li, Lanjuan Li, Qiuxuan Li, Xiancheng Li, Man-Zhi Li, Yanmei Li, De-Jun Li, Junxian Li, Zhihua Li, Keqing Li, Shuwen Li, Danxi Li, Saijuan Li, Minqi Li, Lingjun Li, Mimi Li, Si-Xing Li, Deheng Li, Yingjie Li, Yaodong Li, Shigang Li, Yuan-Hai Li, Lujie Li, Minghao Li, Gao-Fei Li, Minle Li, Meifen Li, Yifeng Li, Le-Le Li, Huanqing Li, Ziwen Li, Yuhang Li, Yongqiu Li, Pu-Yu Li, Jianhua Li, Nan-Nan Li, Chanjuan Li, Lan-Lan Li, Hongming Li, Shuang Li, Yanchuan Li, Lingyi Li, Wanting Li, Bai-Qiang Li, Gong-Hua Li, Zhengyu Li, Chunmiao Li, Jiong-Ming Li, Yongqiang Li, Linsheng Li, Weiguang Li, Mingyao Li, Guoqing Li, Ze Li, Xiaomeng Li, R H L Li, Yuanze Li, Yunqi Li, Yuandong Li, Guisen Li, Jinglin Li, Dongyang Li, Honglong Li, Mingfang Li, Hanmei Li, Chenmeng Li, Changcheng Li, Shiyang Li, Shiyue Li, Jianing Li, Hanbo Li, Dingshan Li, Yinggao Li, Linlin Li, Xinsheng Li, Jin-Wei Li, Jin-Jiang Li, Cheng-Tian Li, Chang Li, Zhi-Xing Li, Yaxi Li, Ming-Han Li, Wei-Ming Li, Wenchao Li, Guangyan Li, Zhaosha Li, Xuesong Li, Jiwei Li, Yongzhen Li, Chun-Quan Li, Weifeng Li, Tao Li, Wenhui Li, Sichen Li, Xiankai Li, Qingsheng Li, Yaxuan Li, Liangji Li, Yuchan Li, Lixiang Li, Tian-wang Li, Jiaxi Li, Yalin Li, Jin-Liang Li, Pei-Zhi Li, Xiaoqiong Li, You Ran Li, Guanyu Li, Yixiao Li, Jinlan Li, Huizi Li, Jianping Li, Kathy H Li, Yun-Lin Li, Yadong Li, Sujing Li, Yuhua Li, Xuri Li, Wenzhuo Li, Y Li, Deqiang Li, Caixia Li, Zipeng Li, Mingyue Li, Hongli Li, Yun Li, Mengqiu Li, Ling-Ling Li, Yaqin Li, Yanfeng Li, Yu-He Li, Shasha Li, S-C Li, Xi Li, Siyi Li, Minmin Li, Manna Li, Chengwen Li, Dawei Li, Shu-Feng Li, Haojing Li, Xun Li, Ming-Jiang Li, Zhiyu Li, Sitao Li, Ziyang Li, Qian Li, Yaochen Li, Tinghua Li, Zhenfen Li, Wenyang Li, Bohao Li, Shuo Li, Wenming Li, Mingxuan Li, Si-Ying Li, Xinyi Li, Jenny J Li, Xue-zhi Li, Anqi Li, Shuai Li, Bingsong Li, Xiaoju Li, Ting Li, Xiaonan Li, Zhenyu Li, Duan Li, Xiang-Yu Li, Lei Li, Hongde Li, Fengqing Li, Na Li, Xunjia Li, Yanchang Li, Huibo Li, Ruixia Li, Nanzhen Li, Chuanfang Li, Bingjie Li, Hongxue Li, Pengsong Li, Ruotian Li, Xiaojing Li, Xinlin Li, Zong-Xue Li, En-Min Li, Chunya Li, Yan Ning Li, Honglin Li, Yu-Ying Li, Jinhua Li, Min-jun Li, Yuanheng Li, Qian-Qian Li, Chunxiao Li, Wenli Li, Shijun Li, Mengze Li, Kuan Li, Baoguang Li, Jie-Shou Li, Kaiwei Li, Zimeng Li, Mengmeng Li, W-B Li, Huangyuan Li, Lili Li, Binkui Li, Junxin Li, Yu-Sheng Li, Wei-Jun Li, Guoyan Li, Junjie Li, Fei-Lin Li, Nuomin Li, Shulin Li, Shanglai Li, Yanyan Li, Yue Li, Taibo Li, Junqin Li, Zhongcai Li, Xueying Li, Jun-Ru Li, JunBo Li, Xiaoqi Li, Zhaobing Li, Xiucui Li, Linxin Li, Haihua Li, Yu-Lin Li, Jen-Ming Li, Tsai-Kun Li, Chen-Chen Li, Shujing Li, Hongquan Li, Chuan F Li, Mengyun Li, Mingna Li, Yanxiang Li, Lanlan Li, Moyi Li, Xiyun Li, Yi-Wen Li, Rulin Li, Huifeng Li, Shihong Li, Ya-Pei Li, Lijuan Li, Shengbin Li, Yuanhong Li, Zhongjie Li, Zhenbei Li, Jingyu Li, Xuewei Li, Shuangshuang Li, Long Li, Wenjia Li, Min-Dian Li, Xiatian Li, Ding-Jian Li, Hongwei Li, Danni Li, Yangxue Li, Xiao-Qiang Li, Chengnan Li, Chuanyin Li, Min Li, Zhenzhou Li, Yiqiang Li, Pengyang Li, Kun-Xin Li, Xiawei Li, Binglan Li, Zesong Li, Xiangpan Li, Yutong Li, Mingfei Li, Shuwei Li, Yingnan Li, Ge Li, Mingdan Li, Xihe Li, Xinzhong Li, Jianfeng Li, Chenyao Li, Jun-Yan Li, Dexiong Li, Rongsong Li, Boru Li, Yinxiong Li, Ruixue Li, Zemin Li, Jixi Li, Chris Li, Jicheng Li, Hong-Yu Li, Chuanning Li, Weijian Li, Changhui Li, Jiafei Li, Yingying Li, Gaizhi Li, Chien-Hsiu Li, Xiangcheng Li, Siqi Li, Dechao Li, Chunxing Li, Wenxia Li, Guoxiang Li, Ziru Li, Qiao-Xin Li, Shu-Fang Li, Huang Li, Qiusheng Li, Man Li, Juxue Li, Weiqin Li, Xinming Li, Huayin Li, Xiao-yu Li, Jianyi Li, Yongjun Li, Guo-Jian Li, Guowei Li, Chenglong Li, Xingya Li, Gongda Li, Nan Li, Wei-Ping Li, Yajun Li, Yipeng Li, Mingxing Li, Nanjun Li, Xin-Yu Li, Chunyu Li, P H Li, Jinwei Li, Xuhua Li, Yu-Xiang Li, Ranran Li, Long Shan Li, Suping Li, Yanze Li, Jason Li, Xiao-Feng Li, Monica M Li, Fengjuan Li, W Li, Xianlun Li, Hainan Li, Qi Li, Yutian Li, Xiaoli Li, Xiliang Li, Shuangmei Li, Ying-Bo Li, Fei Li, Xionghui Li, Duanbin Li, Maogui Li, Dan Li, Sumei Li, Hongmei Li, Kang Li, Peilong Li, Yinghao Li, Xu-Wei Li, Mengsen Li, Lirong Li, Wenhong Li, Quanpeng Li, Audrey Li, Yijian Li, Yajiao Li, Guang Y Li, Xianyong Li, Qilan Li, Shilan Li, Qiuhong Li, Zongyun Li, Xiao-Yun Li, Guang-Li Li, Cheng-Lin Li, Bang-Yan Li, Enxiao Li, Jianrui Li, Yousheng Li, Wen-Ting Li, Guohua Li, Kezhen Li, Xingxing Li, Guoping Li, Ellen Li, A Li, Simin Li, Xue-Nan Li, Weiguo Li, Yijie Li, Xiaoying Li, Shengsheng Li, Suwei Li, Shuyu D Li, Jiandong Li, Ruiwen Li, Fangyong Li, Hong Li, Binru Li, Yuqi Li, Zihua Li, Yuchao Li, Hanlu Li, Xue-Peng Li, Jianang Li, Qing Li, Jiaping Li, Sheng-Tien Li, Shihao Li, Yazhou Li, Jun-Ling Li, Caesar Z Li, Feng Li, Weiyang Li, Lang Li, Peihong Li, Jin-Mei Li, Lisha Li, Feifei Li, Kejuan Li, Qinghong Li, Qiqiong Li, Cuicui Li, Xinxiu Li, Kaibo Li, Chongyi Li, Yi-Ying Li, Hanbing Li, Shaodan Li, Meng-Hua Li, Yongzheng Li, J T Li, Da-Hong Li, Xiao-mei Li, Jiejie Li, Ruihuan Li, Xiangwei Li, Baiqiang Li, Ziliang Li, Yaoyao Li, Mo Li, Yueguo Li, Zheng Li, Ming-Hao Li, Donghe Li, Congfa Li, Wenrui Li, Hongsen Li, Yong Li, Xiuling Li, Jingqi Li, Menghua Li, Ka Li, Kaixin Li, Fuping Li, Zhiyong Li, Jianbo Li, Xing-Wang Li, Xiao-Kang Li, Chong Li, Fugen Li, Hanqi Li, Yangyang Li, Yuwei Li, Dongfang Li, Xiaochen Li, Zizhuo Li, Zhuorong Li, X-H Li, Xianrui Li, Dong Sheng Li, Lan-Juan Li, Zhigao Li, Chenlin Li, Zihui Li, Xiaoxiao Li, Guoli Li, Le-Ying Li, Pengcui Li, Xiaoman Li, Huanqiu Li, Bing-Heng Li, Zhan Li, Weisong Li, Xinglong Li, Xiaohong Li, Xiaozhen Li, Yuan Hao Li, Jianchun Li, Wenxiang Li, Zhaoliang Li, Guo-Ping Li, Zhiyang Li, Cunxi Li, Jinhui Li, Zhifei Li, Ying Li, Yanshu Li, Jianlin Li, Yuanyou Li, Chongyang Li, Yumin Li, Wanyan Li, Guiying Li, Longyu Li, Jinku Li, X B Li, Cuiling Li, Changgui Li, Zhisheng Li, Xuekun Li, Yuguang Li, Wenke Li, Jiayi Li, Jianguo Li, En Li, Ximei Li, Shaoyong Li, Peihua Li, Kai-Wen Li, Suwen Li, Chang-Ping Li, Guangda Li, Yixue Li, Guandu Li, Junfeng Li, Xin-Chang Li, Jieming Li, Kongdong Li, Yue-Ying Li, Chunhui Li, Peiyu Li, Tongyao Li, Lian Li, Linfeng Li, Yuzhe Li, Xinmiao Li, Chenyang Li, Jiacheng Li, Chang-Yan Li, Qifang Li, Xiaohua Li, Vivian Li, Duanxiang Li, Xiaolin Li, Meiting Li, Justin Li, Xue-Er Li, Zhuangzhuang Li, Hongchang Li, Xiaohui Li, Cang Li, Xuepeng Li, Mingjiang Li, Youwei Li, Ronggui Li, Xingwang Li, Tiange Li, Yongjia Li, Dacheng Li, Xinmin Li, Zongyu Li, Luquan Li, Jianyong Li, Shujie Li, Guoxing Li, Zongchao Li, Yanbin Li, Shiliang Li, Jia Li, Haimin Li, Qinrui Li, Sheng-Qing Li, Yiming Li, Xiao-Tong Li, Lingjie Li, Yiwen Li, Tie Li, Baoqi Li, Leyao Li, Wei-Bo Li, Xiaoyi Li, Liyan Li, Xiao-Qin Li, Xiaokun Li, Xinke Li, Ming-Wei Li, Minzhe Li, Wenfeng Li, Jiajing Li, Karen Li, Yanlin Li, X Li, Liao-Yuan Li, Meifang Li, Yanjing Li, Yongkai Li, Maosheng Li, Ju-Rong Li, Shibo Li, Jin Li, Hangwen Li, Li-Na Li, Hengguo Li, An-Qi Li, Xuehua Li, Hui Li, AnHai Li, Chenli Li, Zhengrui Li, Rumei Li, Fangqi Li, Xiaoguang Li, Xian Li, Danjie Li, Yan-Yu Li, Vivian S W Li, Qinghua Li, Qinqin Li, Lipeng Li, Leilei Li, Defu Li, Ranchang Li, Lianyong Li, Amy Li, Zhou Li, Q Li, Haoyu Li, Xiaoyao Li, M-J Li, Jiao-Jiao Li, Zhu Li, Rongling Li, Tong-Ruei Li, Bizhi Li, Cheng-Wei Li, Wenwen Li, Guangqiang Li, Jian'an Li, Ben Li, Sichong Li, Wenyi Li, Yingxia Li, Meiyan Li, Qing-Min Li, Yonghe Li, Yun-Da Li, Xinwei Li, Shunhua Li, Yu-I Li, Mingxi Li, Jian-Qiang Li, Yingrui Li, Chenfeng Li, Qionghua Li, Guo-Li Li, Xingchen Li, Ziqi Li, Shen Li, Tianjiao Li, Shufen Li, Gui-Rong Li, Yunfeng Li, Yunpeng Li, Yueqi Li, Qiong Li, Xiao-Guang Li, Jiali Li, Zhencheng Li, Qiufeng Li, Songyu Li, Xu Li, Pinghua Li, Shi-Fang Li, Shude Li, Yaxiong Li, Zhibin Li, Zhenli Li, Qing-Fang Li, Rosa J W Li, Yunxiao Li, Hsin-Yun Li, Shengwen Li, Gui-Bo Li, XiaoQiu Li, Xueer Li, Zhankui Li, Zhi Li, Zihai Li, Yue-Jia Li, Haihong Li, Peifen Li, Mingzhou Li, Taixu Li, Jiejing Li, Meng-Miao Li, Meiying Li, Chunlian Li, Zhijie Li, Meng Li, Cun Li, Huimin Li, Ruifang Li, T Li, Xiao-xu Li, Man-Xiang Li, Cong Li, Yinghui Li, Chengbin Li, Feilong Li, Yuping Li, Sin-Lun Li, Mengfan Li, Weiling Li, Jie Li, Shiyan Li, Lianbing Li, G Li, Yanchun Li, Xuze Li, Zhi-Yong Li, Yukun Li, Wenjian Li, Jialin Li, He Li, Bichun Li, Xiong Bing Li, Hanqin Li, Qingjie Li, Wen Lan Li, Guoge Li, Han Li, Wen-Wen Li, Keying Li, Yutang Li, Minze Li, Xingcheng Li, Wanshun Li, Congxin Li, Hankun Li, Hongling Li, Xiangrui Li, Chaojie Li, Caolong Li, Michelle Li, Zhifan Li, J Li, Zhi-Jian Li, Jianwei Li, Yan-Guang Li, Jiexin Li, Hongyan Li, Ji-Min Li, Zhen-Xi Li, Guangdi Li, Peipei Li, Tian-Yi Li, Xiaxia Li, Yuefeng Li, Nien Li, Zhihao Li, Peiyuan Li, Yao Li, Zheyun Li, Tiansen Li, Chi-Yuan Li, Xiangfei Li, Xue Li, Zhonglin Li, Fen Li, Lin Li, Jieshou Li, Chenjie Li, Jinfang Li, Roger Li, Yanming Li, Ben-Shang Li, Hong-Lan Li, Mengqing Li, S L Li, Ming-Kai Li, Shunqing Li, Xionghao Li, Lan Li, Menglu Li, Huiqing Li, Yanwei Li, Yantao Li, Chien-Te Li, Wenyan Li, Xiaoheng Li, Zeyuan Li, Yongle Li, Ruolin Li, Hongqin Li, Zhenhao Li, Jonathan Z Li, Haying Li, Shao-Dan Li, Muzi Li, Yong-Liang Li, Gen Li, Dong-Ling Li, M Li, Chenwen Li, Jiehan Li, Yong-Jian Li, Le Li, Hongguo Li, Chenxin Li, Yongsen Li, Qingyun Li, Pengyu Li, Si-Wei Li, Ai-Qin Li, Zichao Li, Manru Li, Caili Li, Yingxi Li, Yuqian Li, Guannan Li, Wei-Dong Li, Cien Li, Qingyu Li, Xijing Li, Jingshang Li, Xingyuan Li, Dehua Li, Wenlong Li, Ya-Feng Li, Yanjiao Li, Jia-Huan Li, Yuna Li, Guoxi Li, Xudong Li, Xingfang Li, Shengli Li, Shugang Li, Jisheng Li, Rongyao Li, Xuan Li, Yongze Li, Yongxin Li, Ru Li, Lu Li, Jiangya Li, Yiche Li, Yilang Li, Zhuo-Rong Li, Bingbing Li, Qinglin Li, Runzhi Li, Yunshen Li, Jingchun Li, Qi-Jing Li, Hexin Li, Zhenyan Li, H J Li, Yanping Li, Ji Xia Li, Yu-Ye Li, Meizi Li, Qing-Wei Li, Qiang Li, Yuezheng Li, Hsiao-Hui Li, Zhengnan Li, L I Li, Jianglong Li, Hongzheng Li, Laiqing Li, Zhongxia Li, Ningyang Li, Guangquan Li, Xiaozheng Li, Hui-Jun Li, Shun Li, Guojun Li, Xuefei Li, Senlin Li, Hung Li, Jinping Li, Huili Li, Sainan Li, Jinghui Li, Zulong Li, Chengsi Li, P Li, Hongzhe K Li, Xiao-Qiu Li, Fulun Li, Jiejia Li, Yonghao Li, Mingli Li, Yehong Li, Zhihui Li, Yi-Yang Li, Fujun Li, Pei Li, Quanshun Li, Yongping Li, Liguo Li, Ni Li, Weimin Li, Mingxia Li, Xue-Hua Li, M V Li, Luxuan Li, Qiang-Ming Li, Yakui Li, Huafu Li, Xinye Li, Shichao Li, Gan Li, Chunliang Li, Ruiyang Li, Dapei Li, Zejian Li, Lihong Li, Chun Li, Jianan Li, Wenfang Li, Haixia Li, Sung-Chou Li, Xiangling Li, Lianhong Li, Jingmei Li, Ao Li, Yitong Li, Siwen Li, Yanlong Li, Cheng Li, Kui Li, Zhao Li, Tiegang Li, Yunxu Li, Zhong Li, Shuang-Ling Li, Xiao-Long Li, Hung-Yuan Li, Xiaofei Li, Xuanfei Li, Zilin Li, Zhang Li, Jianxin Li, Mingqiang Li, Xiaojiao Li, H Li, Dongliang Li, Yinzhen Li, Chenxiao Li, Hongjia Li, Xiao-Jing Li, Yunsheng Li, Li-Min Li, Xiangqi Li, Jian Li, Y H Li, Jia-Peng Li, Baichuan Li, Daoyuan Li, Haibo Li, Wenqi Li, Zhenzhe Li, Xiao-Jun Li, Jian-Mei Li, Kaimi Li, Yan-Hong Li, Peiran Li, Shi Li, Xueling Li, Qiao Li, Yi-Yun Li, Xiao-Cheng Li, Conghui Li, Xiaoxiong Li, Wanni Li, Yike Li, Yihan Li, Chitao Li, Haiyang Li, Jiayu Li, Xiaobai Li, Junsheng Li, Pingping Li, Mingquan Li, Wen-Ya Li, Suran Li, Yunlun Li, Rongxia Li, Yingqin Li, Yuanfang Li, Guoqin Li, Qiner Li, Huiqin Li, Shanhang Li, Jiafang Li, Chunlin Li, Han-Bing Li, Zongzhe Li, Yikang Li, Jisen Li, Si-Yuan Li, Caihong Li, Hongmin Li, Peng Peng Li, Yajing Li, Guanglu Li, Kenli Li, Benyi Li, Yuquan Li, Xiushi Li, Hongzhi Li, Jian-Jun Li, Dongmin Li, Fengyi Li, Yanling Li, Chengxin Li, Juanni Li, Xiaojiaoyang Li, C Li, Xinxin Li, Jian-Shuang Li, You-Mei Li, Yubin Li, Chenglan Li, Dazhi Li, Beixu Li, Yuhong Li, Fengqiao Li, Di Li, Guiyuan Li, Yanbing Li, Suk-Yee Li, Yuanyuan Li, Shengjie Li, Jufang Li, Xiaona Li, Shanyi Li, Hongbo Li, Chih-Chi Li, Xinhui Li, Zecai Li, Qipei Li, Xiaoning Li, Jun Li, Minghua Li, Xiyue Li, Zhuoran Li, Tianchang Li, Hongru Li, Shiqi Li, Mei-Ya Li, Wuyan Li, Mingzhe Li, Yi-Ling Li, Hongjuan Li, Yingjian Li, Zhirong Li, Wang Li, Mingyang Li, Weijun Li, Boyang Li, Senmao Li, Cai Li, Mingjie Li, Ling-Jie Li, Hong-Chun Li, Jingcheng Li, Ivan Li, Yaying Li, Mengshi Li, Liqun Li, Manxia Li, Ya Li, Changxian Li, Wen-Chao Li, Dan-Ni Li, Sunan Li, Zhencong Li, Chunqing Li, Jiong Li, Lai K Li, Yanni Li, Daiyue Li, Bingong Li, Huifang Li, Xiujuan Li, Yongsheng Li, Lingling Li, Chunxue Li, Yunlong Li, Xinhua Li, Jianshuang Li, Juanling Li, Minerva X Li, Xinbin Li, Alexander H Li, Xue-jing Li, Ding Li, Yuling Li, Wendeng Li, Xianlin Li, Yetian Li, Chuangpeng Li, Mingrui Li, Linyan Li, Yanjun Li, Shengze Li, Ming-Yang Li, Jiequn Li, Zhongding Li, Hewei Li, Da-Jin Li, Jiangui Li, Zhengyang Li, Cyril Li, Xinghui Li, Yuefei Li, Xiao-kun Li, Xinyan Li, Yuanhao Li, Xiaoyun Li, Congcong Li, Ji-Lin Li, Yushan Li, Ping'an Li, Juan Li, Weiping Li, Huan Li, Changjiang Li, Chengping Li, G-P Li, He-Zhen Li, Xiaobin Li, Shaoqi Li, Yuehua Li, Yinliang Li, Wen Li, Jinfeng Li, Shiheng Li, Yu-Kun Li, Weihai Li, Jiangan Li, Hsiao-Fen Li, Zhaojin Li, Mengjiao Li, Bingxin Li, Wenjuan Li, Wenyu Li, Chia-Yang Li, Meng-Meng Li, Tianxiang Li, Liangkui Li, Tian-chang Li, Hairong Li, Yahui Li, Su Li, Xi-Xi Li, Wenlei Li, Mei-Lan Li, Wenjun Li, Jiaxin Li, Haiyan Li, Ming D Li, Chenguang Li, Ruyue Li, Xujun Li, Chi-Ming Li, Xiaolian Li, Dandan Li, Yi-Ning Li, Yunan Li, Jiazhou Li, Zechuan Li, Zhijun Li, Sherly X Li, Wanling Li, Ya-Ge Li, Yinyan Li, Qijun Li, Rujia Li, Guangli Li, Lixia Li, Zhiwei Li, Xueshan Li, Yunrui Li, Yuhuang Li, Shanshan Li, Jiangbo Li, Xiaohan Li, Wan-Shan Li, Zhongwen Li, Huijie Li, W W Li, Yalan Li, Yiyang Li, Jing-gao Li, Xuejun Li, Fengxiang Li, Nana Li, Shunwang Li, Chao Li, Yaqing Li, Bingsheng Li, Yaqiao Li, Jingui Li, Huamao Li, Xiankun Li, Jingke Li, Tianyao Li, Xiaowei Li, Junming Li, Jianfang Li, Shubo Li, Qi-Fu Li, Zi-Zhan Li, Hai-Yun Li, Haoran Li, Zhongxian Li, Xiaoliang Li, Xinyuan Li, Maoquan Li, H-J Li, Zhixiong Li, Chumei Li, Shijie Li, Lingyan Li, Zhanquan Li, Wenguo Li, Fangyuan Li, Xuhang Li, Xiaochun Li, Chen-Lu Li, Jialun Li, Xinjian Li, Rui Li, Zilu Li, Xuemin Li, Zezhi Li, Sheng-Fu Li, Xue-Fei Li, Yudong Li, Shanpeng Li, Hongjiang Li, Wei-Na Li, Dong-Run Li, Yunxi Li, Jingyun Li, Xuyi Li, Binghua Li, Hanjun Li, Yunchu Li, Jin-Qiu Li, Qihua Li, Zhengyao Li, Jiaxuan Li, Jinghao Li, Y-Y Li, Xiaofang Li, Tuoping Li, Pengyun Li, Guangjin Li, Lin-Feng Li, Xutong Li, Ranwei Li, Kai Li, Ziqing Li, Keanning Li, Wei-Li Li, Yongjin Li, Shuangxiu Li, Chenhao Li, Ling Li, Weizu Li, Deming Li, Peiqin Li, Xiaodong Li, Nanxing Li, Qihang Li, Jianrong Li, Baoguo Li, Zhehui Li, Chenghao Li, Jiuyi Li, Chun-Xu Li, Luyao Li, Weike Li, Desheng Li, Zhixuan Li, Chuanbao Li, Long-Yan Li, Fuyu Li, Chuzhong Li, M D Li, Lingzhi Li, Yuan-Tao Li, Kening Li, Guilan Li, Wanshi Li, Hengtong Li, Ling-Zhi Li, Yifan Li, Ya-Li Li, Xiao-Sa Li, Songyun Li, Xiaoran Li, Bolun Li, Kunlin Li, Linchuan Li, Jiachen Li, Haibin Li, Shu-Qi Li, Zehua Li, Huangbao Li, Guo-Chun Li, Xinli Li, Mengyuan Li, S Li, Wenqing Li, Wenhua Li, Caiyun Li, Congye Li, Xinrui Li, Dehai Li, Wensheng Li, Jiannan Li, Qingshang Li, Guanbin Li, Zhiyi Li, Hanbin Li, Xing Li, Wanwan Li, Jia Li Li, Zhaoyong Li, SuYun Li, Shiyi Li, Wan-Hong Li, Mingke Li, Suchun Li, Xiaoyuan Li, Huanhuan Li, Yanan Li, Zongfang Li, Yang Li, Jiayan Li, YueQiang Li, Xiangping Li, H-H Li, Jinman Li, BoWen Li, Duoyun Li, Yimei Li, Dongdong Li, Hao Li, Liliang Li, Mengxi Li, Keyuan Li, Zhi-qiang Li, Shaojing Li, S S Li, Yi-Ting Li, Jiangxia Li, Yujie Li, Tong Li, Lihua Li, Yilong Li, Xue-Lian Li, Zhiping Li, Yan-Li Li, Haiming Li, Yansen Li, Gaijie Li, Hai Li, Yuemei Li, Yanli Li, Jingfeng Li, Zhi-Yuan Li, Kaibin Li, Yuan-Jing Li, Xuefeng Li, Wenjie Li, Xiaohu Li, Ruikai Li, Mengjuan Li, Xiao-Hong Li, Yinglin Li, Yaofu Li, Ren-Ke Li, Qiyong Li, Ruixi Li, Yi Li, Zhonglian Li, Baosheng Li, Yujun Li, Mian Li, Dalin Li, Lixi Li, Jin-Xiu Li, Kun Li, Qizhai Li, Jiwen Li, Pengju Li, Peifeng Li, Zhouhua Li, Ai-Jun Li, Qingqin S Li, Honglei Li, Guojin Li, Yueting Li, Xin-Yue Li, Dingchen Li, YaJie Li, Xiaoling Li, Jixuan Li, Yanqing Li, Zijian Li, Zhandong Li, Xuejie Li, Peining Li, Congjiao Li, Meng-Jun Li, Gaizhen Li, Huilin Li, Liang Li, Songtao Li, Fusheng Li, Huafang Li, Dai Li, Meiyue Li, Chenlu Li, Keshen Li, Kechun Li, Nianyu Li, Yuxin Li, X-L Li, Shaoliang Li, Shawn S C Li, Shu-Xin Li, Hong-Zheng Li, Tianye Li, Dongye Li, Qun Li, Cuiguang Li, Zhen Li, Yuan Li, Chunhong Li, F Li, Mengling Li, Kunpeng Li, Jia-Da Li, Zhenghao Li, Chun-Bo Li, Zhantao Li, Baoqing Li, Pu Li, Xinle Li, Xingli Li, Bingkun Li, Nien-Chi Li, Wuguo Li, Tiewei Li, Bing-Hui Li, Rong-Bing Li, Daniel Tian Li, Honggang Li, Jingyong Li, Wei-Yang Li, Rong Li, Shikang Li, Mingkun Li, Binxing Li, Shi-Ying Li, Zixiao Li, Ming Xing Li, Guixin Li, Quanzhang Li, Ming-Xing Li, Marilyn Li, Da-wei Li, Shishi Li, Bei-Bei Li, Hong-Lian Li, Xiumei Li, Haitong Li, Melody M H Li, Ruibing Li, Yuli Li, Qingfang Li, Peibo Li, Qibing Li, Huanjun Li, Heng Li, Wende Li, Chung-Hao Li, Liuzheng Li, Zhanjun Li, Yifei Li, Tianming Li, Chang-Sheng Li, Xiao-Na Li, Tianyou Li, Jipeng Li, Xidan Li, Yixing Li, Chengcheng Li, Yu-Jin Li, Longxuan Li, Baoting Li, Huiyou Li, Ka Wan Li, Shi-Guang Li, Wenxiu Li, Binbin Li, Xinyao Li, Zhuang Li, Yu-Hao Li, Gui-xing Li, Shilin Li, Shunle Li, Niu Li, Siyue Li, Diyan Li, Shili Li, Mengyao Li, Yixuan Li, Shan-Shan Li, Zhuanjian Li, Meiqing Li, Gerard Li, Yuyun Li, Hengyu Li, Zhiqiong Li, Yinhao Li, Zonglin Li, Pik Yi Li, Junying Li, Jingxin Li, Mufan Li, Chun-Lai Li, Defeng Li, Shiya Li, Zu-guo Li, Xin-Zhu Li, Xiao-Jiao Li, Jia-Xin Li, Kuiliang Li, Pindong Li, Hualian Li, Youchen Li, Junhong Li, Li Li, W Y Li, Hanxue Li, Lulu Li, Yi-Heng Li, Xiaoqin Li, L P Li, Runbing Li, Chunmei Li, Mingjun Li, Yuanhua Li, Qiaolian Li, Yanmin Li, Ji-Cheng Li, Jingyi Li, Yuxiang Li, Haolong Li, Hao-Fei Li, Xuanzheng Li, Peng-li Li, Quan Li, Yining Li, Xue-Ying Li, Xiurong Li, Huijuan Li, Haiyu Li, Xu-Zhao Li, Yunze Li, Yanzhong Li, Kainan Li, Guohui Li, Yongzhe Li, Qingfeng Li, Xiaoyan Li, Tianyi Li, Nanlong Li, Ping Li, Xu-Bo Li, Fangzhou Li, Nien-Chen Li, Yue-Chun Li, Jiahui Li, Huiping Li, Kangyuan Li, Yuanchuang Li, Biao Li, Haiying Li, Yunting Li, Xiaoxuan Li, Anyao Li, Hongliang Li, Qing-Chang Li, Hong-Yan Li, Shengbiao Li, Yue-Rui Li, Ruidong Li, Dalei Li, Zongjun Li, Y M Li, Changqing Li, Hanting Li, Dong-Jie Li, Sijie Li, Dengxiong Li, Xiaomin Li, Meilan Li, D C Li, Andrew C Li, Jianye Li, Yi-Shuan J Li, Tinghao Li, Zhouxiang Li, Qiuyan Li, Tingguang Li, Yun-tian Li, Jianliang Li, Xiangyang Li, Guangzhao Li, Yixi Li, Chunjie Li, Shuyu Dan Li, S A Li, Tianfeng Li, Anna Fen-Yau Li, Minghui Li, Jiangfeng Li, Jinjie Li, Liming Li, Jie-Pin Li, Junyi Li, Kaiyi Li, Wenqun Li, Dongtao Li, Fengyuan Li, Guixia Li, Yinan Li, Aoxi Li, Zuo-Lin Li, Chenxi Li, Yuanjing Li, Zhengwei Li, Linqi Li, Bingjue Li, Xixi Li, Binghu Li, Yan-Chun Li, Suiyan Li, Yu-Hang Li, Qiaoqiao Li, Zhenguang Li, Xiaotian Li, Jia-Ru Li, Shuhui Li, Pei-Qin Li, Shu-Hong Li, Chun-Xiao Li, Shuyue Li, Mengying Li, Tongzheng Li, Fangyan Li, Quan-Zhong Li, Yihong Li, Duo Li, Dali Li, Yaxian Li, Zhiming Li, Xuemei Li, Xueting Li, Hongxia Li, Yongting Li, Zhenjun Li, Danyang Li, Ren Li, Tiandong Li, Lanfang Li, Hongye Li, Di-Jie Li, Mingwei Li, Bo Li, Jinliang Li, Wenxin Li, Qiji Li, W J Li, Zhipeng Li, Zhijia Li, Xiaoping Li, Jingtong Li, Linhong Li, Taoyingnan Li, Lucy Li, Lieyou Li, Zhengpeng Li, Xiayu Li, Huabin Li, Mao Li, Baolin Li, Cuilan Li, Yuting Li, Yongchao Li, Xiaobo Li, Xiaoting Li, Ruotai Li, Meijia Li, Shujiao Li, Yaojia Li, Weirong Li, Kun-Ping Li, Xiao-Yao Li, Weihua Li, Shangming Li, Yaqi Li, Yibo Li, Gui-Hua Li, Zhihong Li, Runzhao Li, Yandong Li, Chaowei Li, Xiang-Dong Li, Huiyuan Li, Yuchun Li, Yingjun Li, Xiufeng Li, Yanxin Li, Xiaohuan Li, Ying-Qin Li, Boya Li, Lamei Li, O Li, Fan Li, Jun Z Li, Joyce Li, Suheng Li, Yiheng Li, Taiwen Li, Hui-Ping Li, Xiaorong Li, Zhiqiang Li, Junru Li, Hecheng Li, Jiangchao Li, Haifeng Li, Changkai Li, Yueping Li, Liping Li, Rena Li, Jiangtao Li, Yu-Jui Li, Zhenglong Li, Yajuan Li, Rui-Jún Eveline Li, Xuanxuan Li, Bing-Mei Li, Yunman Li, Chaoqian Li, Shuhua Li, Yu-Cheng Li, Chunying Li, Yirun Li, Haomiao Li, Weiheng Li, Leipeng Li, Qianqian Li, Baizhou Li, Zhengliang Li, YiQing Li, Han-Ru Li, Sheng Li, Weijie Li, Wei-Qin Li, Yaqiang Li, Guoyin Li, Zongyi Li, Qingxian Li, Dan-Dan Li, Yeshan Li, Qiwei Li, Zirui Li, Yongpeng Li, Chengjun Li, Keke Li, Jianbin Li, Chanyuan Li, Shiying Li, Jianxiong Li, Huaying Li, Ji Li, Tuojian Li, Yixin Li, Ziyue Li, Zhongzhe Li, Juntong Li, Xiang Li, Yumei Li, Xiang-Ping Li, Chaonan Li, Wenqiang Li, Yu-Chia Li, Pei-Shan Li, Zaibo Li, Shaomin Li, Heying Li, Guangming Li, Xuan-Ling Li, Yuxuan Li, Bingshan Li, Xiaoqiang Li, Jiahao Li, Hanxiao Li, Jiansheng Li, Shuying Li, Shibao Li, Xiaomei Li, Kunlong Li, Pengjie Li, Ruijin Li
articles
Yi Han, Yun Hong, Yan Gao +11 more · 2025 · PLoS genetics · PLOS · added 2026-04-24
Heart failure (HF) is a serious cardiovascular condition resulting from abnormalities in multiple biological processes, affecting over 64 million people worldwide. We sought to expand our understandin Show more
Heart failure (HF) is a serious cardiovascular condition resulting from abnormalities in multiple biological processes, affecting over 64 million people worldwide. We sought to expand our understanding of the genetic basis of HF and more specific NICM subtype in the East Asian populations and evaluate the biological pathways underlying subclinical left ventricular dysfunction. We conducted a meta-analysis of genome-wide association studies (GWAS) for all-cause HF in the East Asian populations (N cases ~ 13,385) and a more precise definition of nonischemic cardiomyopathy (NICM) subtype in multi-ancestry populations (N cases~3,603). We identified a low-frequency East-Asian enriched coding variant near MYBPC3 and a NICM specific locus. Follow up analyses demonstrated male-specific HF association at the MYBPC3 locus, and highlighted SVIL as a candidate causal gene for NICM. Moreover, we demonstrated that SVIL deficiency aggravated cardiomyocyte hypertrophy, apoptosis and impaired cell viability in phenylephrine (PE)-treated H9C2 cells. In addition, the gene expression level of B-type natriuretic peptide (BNP) which was deemed as a hallmark for HF was further elevated by SVIL silencing in PE-stimulated H9C2 cells. RNA-sequencing analysis of H9C2 cells revealed that the function of SVIL might be mediated through pathways relevant to regulation and differentiation of heart muscle. These results enhance our understanding of the genetic architecture of HF in the East Asian populations, and provide important insight into the biological pathways underlying NICM and sex-specific relevance of the MYBPC3 locus that warrants further replication in another datasets. Show less
📄 PDF DOI: 10.1371/journal.pgen.1011897
MYBPC3
Yanping Wang, Xiaoru Ma, Zhixin Qiao +16 more · 2025 · Journal of neuroinflammation · BioMed Central · added 2026-04-24
Astrocytes are key regulators of neuroinflammation in multiple sclerosis (MS). Electroacupuncture (EA), a safe and cost-effective adjuvant therapy, has shown benefits in neurodegenerative diseases, bu Show more
Astrocytes are key regulators of neuroinflammation in multiple sclerosis (MS). Electroacupuncture (EA), a safe and cost-effective adjuvant therapy, has shown benefits in neurodegenerative diseases, but its astrocyte-related mechanisms remain unclear. Here, we demonstrated that EA at ST36 alleviated blood-brain barrier (BBB) disruption and neuroinflammation during the peak period of experimental autoimmune encephalomyelitis (EAE). Additionally, EA at ST36 upregulated the expression of α-melanocyte-stimulating hormone (α-MSH) and its receptor melanocortin-4 receptor (MC4R) in spinal astrocytes. Pharmacological studies showed that MC4R agonist RO27-3225 mimicked the therapeutic effects of EA, whereas MC4R antagonist TCMCB07 weakened EA-mediated BBB protection and neuroinflammation suppression. Moreover, astrocyte-specific silencing of MC4R via adeno-associated virus (AAV) weakened EA-mediated BBB protection and neuroinflammation suppression. RNA-sequencing (RNA-seq) and western blot (WB) revealed that EA exerts neuroprotective effects by activating MC4R to inhibit MAPK and NF-κB signaling pathways. Moreover, in MC4R-overexpressing astrocytes, α-MSH and RO27-3225 reduced inflammation responses, while TCMCB07 reversed the effects by MAPK/NF-κB signaling pathways. Collectively, our findings identify astrocytic MC4R as a critical mediator of EA-driven neuroprotection by suppressing MAPK/NF-κB signaling, providing mechanistic insight and a promising therapeutic target for EAE and other neuroinflammatory disorders. Show less
📄 PDF DOI: 10.1186/s12974-025-03667-1
MC4R
Wenyong Li, Rudi Lv, Husong Su +4 more · 2025 · Scientific reports · Nature · added 2026-04-24
The Kruppel-like factor 15(KLF15) gene functions as a crucial transcriptional modulator involved in numerous cellular processes such as differentiation, proliferation, growth, and programmed cell deat Show more
The Kruppel-like factor 15(KLF15) gene functions as a crucial transcriptional modulator involved in numerous cellular processes such as differentiation, proliferation, growth, and programmed cell death. The epithelial-to-mesenchymal transition (EMT) provides malignant cells with the adaptability and movement necessary for tumor advancement and spread, with zinc finger E-box binding homeobox 1(ZEB1) playing a pivotal role as a transcriptional factor in EMT. This investigation initially examined the association between the KLF15 protein and EMT associated transcription factors such as ZEB1, Slug, and Snail, along with marker proteins like E-cadherin and β-catenin in bladder cancer. Furthermore, we explored their connections with clinicopathological attributes and conducted prognostic analyses. Immunohistochemical techniques were utilized to ascertain the presence of KLF15 protein and EMT-associated transcription factor proteins, along with their marker proteins in 110 specimens of bladder cancer tissues. Concurrently, clinicopathological data and postoperative survival statistics were amassed. The rates of KLF15 and Slug protein expression were linked with pathological differentiation, lymphatic involvement, and pTNM staging. The protein expression rates of ZEB1, Slug, Snail, E-cadherin, and β-catenin also showed associations with lymphatic metastasis and pTNM stages. Notably, the expression of KLF15, the coexpression of KLF15 and ZEB1, and lymphatic metastasis emerged as independent prognostic indicators for the overall survival rates in bladder cancer cases. EMT enhances the risk of tumor recurrence and reduces overall survival durations in bladder cancer cases. Furthermore, KLF15 is a significant contributor to the EMT pathway in bladder cancer, primarily through its interaction with the transcription factor ZEB1. KLF15 and ZEB1 might serve as key biomarkers for metastasis and prognosis, offering potential new targets for therapeutic intervention in bladder cancer. Show less
no PDF DOI: 10.1038/s41598-025-22698-5
SNAI1
Nafeisha Simayi, Jiaying Li, Junkai Hu +4 more · 2025 · Frontiers in immunology · Frontiers · added 2026-04-24
Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase i Show more
Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear. A vascularized microfluidic chip was applied to model angiogenesis, together with Bevacizumab plus anlotinib (B+A) inhibited angiogenesis, reducing vessel density to 10% of control values and also reducing diameter and green fluorescent protein (GFP) area ratio. B+A inhibited cell viability by 78%, colony formation by 90%, and invasion by 75% in NSCLC cell lines A549 and H1299; downregulated N-cadherin 5.34-fold, vimentin 6.46-fold, and α-SMA 4.35-fold; and upregulated E-cadherin 3.75-fold. The rates of apoptosis of A549 and H1299 cells were increased 3.85-fold. The phosphorylation of VEGFR2, PDGFRβ, and FGFR1 was also reduced. B+A reduced tumor volume 7.23-fold and weight 7.08-fold, decreased tumor cell density, and lowered Ki-67 expression in an HIF-1α inhibitor PX478 did not enhance the anti-tumor effects of B+A, but HIF-1α activator DMOG reversed them. In addition, the combination therapy enhanced CD4 Show less
📄 PDF DOI: 10.3389/fimmu.2025.1613368
FGFR1
Fenglou He, Han Liu, Yakun Yao +6 more · 2025 · International journal of molecular sciences · MDPI · added 2026-04-24
This study aimed to collaboratively investigate the mechanism of variations in intramuscular fat (IMF) content in Wandong cattle using transcriptomics and metabolomics techniques. Longissimus dorsi (L Show more
This study aimed to collaboratively investigate the mechanism of variations in intramuscular fat (IMF) content in Wandong cattle using transcriptomics and metabolomics techniques. Longissimus dorsi (LD) muscle samples were collected from thirteen free-range Wandong cattle in Fengyang County, Anhui Province, China. From this initial cohort, eight animals closely matched in age and body weight were selected. Based on IMF content measured by Soxhlet extraction, these eight cattle were divided into two groups: the high-IMF (HF, n = 4) and low-IMF (LF, n = 4) groups. Subsequent analyses were performed on integrated datasets comprising the transcriptome, metabolome, and fatty acid profile. The results revealed a significant increase in IMF in the HF group compared to the LF group ( Show less
📄 PDF DOI: 10.3390/ijms262311557
HSD17B12
Huatao Zheng, Dan Li, Rentao Ma +3 more · 2025 · Frontiers in public health · Frontiers · added 2026-04-24
With the aging population in China, research on preventing frailty is crucial. This study aims to investigate the independent and combined associations of the Dietary inflammatory index (DII) and phys Show more
With the aging population in China, research on preventing frailty is crucial. This study aims to investigate the independent and combined associations of the Dietary inflammatory index (DII) and physical activity (PA) with frailty among Chinese older adults. A total of 285 participants aged ≥60 years with 87 males and 186 females were recruited from Hunan Province. Daily moderate physical activity (MPA), vigorous physical activity (VPA) and light physical activity (LPA) were objectively measured using a triaxial accelerometer. A Food Frequency Questionnaire 25 (FFQ25) was used to assess the participants' dietary patterns, and DII was calculated. Six combined exposure groups were formed based on PA and DII: pro-inflammatory diet and insufficient PA group, neutral diet and insufficient PA group, anti-inflammatory diet and insufficient PA group, pro-inflammatory diet and sufficient PA group, neutral diet and sufficient PA group, and anti-inflammatory diet and sufficient PA group. Frailty was assessed using the Frailty Phenotype (FP), logistic regression analyzed the associations between dietary patterns, PA, and frailty. A total of 285 older adults participants were initially recruited, but 12 were excluded due to missing data. Consequently, 273 participants were included in the final analysis. Compared to individuals with insufficient PA, those with sufficient PA were associated with significantly lower odds of frailty (OR = 0.468, 95%CI = 0.242-0.907). Participants following an anti-inflammatory diet had significantly lower odds of frailty compared with those following a pro-inflammatory diet (OR = 0.467, 95%CI = 0.221-0.988). In the combined groups, frailty prevalence was significantly lower the group with anti-inflammatory diet and sufficient PA group (OR = 0.204, 95%CI = 0.072-0.583), compared with pro-inflammatory diet and insufficient PA group. The sensitivity analysis showed that the associations between anti-inflammatory diet and sufficient PA with frailty remained statistically significant, with the direction of the associations unchanged. These findings suggest that the results are robust. Our study indicates that adhering to an anti-inflammatory diet and maintaining sufficient PA may be associated with a lower likelihood of frailty. Achieving an adequate amount of PA and following a healthy dietary pattern may serve as potential preventive measures against frailty. Show less
📄 PDF DOI: 10.3389/fpubh.2025.1739530
LPA
Giuliana Ascone, Rajdeep Kaur, Arwaa Mehran +14 more · 2025 · bioRxiv : the preprint server for biology · Cold Spring Harbor Laboratory · added 2026-04-24
Osteoglophonic Dysplasia (OGD) is an autosomal dominant skeletal dysplasia characterized by impaired bone growth resulting in short stature, severe craniofacial abnormalities, and in some patients FGF Show more
Osteoglophonic Dysplasia (OGD) is an autosomal dominant skeletal dysplasia characterized by impaired bone growth resulting in short stature, severe craniofacial abnormalities, and in some patients FGF23-mediated hypophosphatemia. It is caused by gain-of-function variants in FGFR1, particularly in or near the transmembrane domain of the receptor. We used CRISPR in mice to knock-in the FGFR1 p.N330I variant, chosen based on its association with FGF23 excess. Skeletal phenotyping of this Show less
📄 PDF DOI: 10.1101/2025.11.14.680268
FGFR1
Y X Li, H X Peng, H D Guo +11 more · 2025 · Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi · added 2026-04-24
With the advancement of genomic technologies, precision lifestyle interventions tailored to individual genetic backgrounds have emerged as a novel approach for preventing and managing chronic diseases Show more
With the advancement of genomic technologies, precision lifestyle interventions tailored to individual genetic backgrounds have emerged as a novel approach for preventing and managing chronic diseases such as obesity. Several randomized controlled trials (RCTs) targeting obese or overweight populations have found that individuals with different genotypes exhibit varying responses to the same lifestyle intervention (gene-lifestyle intervention interactions). To date, more than 20 genes, including Show less
no PDF DOI: 10.3760/cma.j.cn112338-20250501-00297
MC4R
Ya-Ting Chen, Jing Sui, Yu Yang +16 more · 2025 · BMC medicine · BioMed Central · added 2026-04-24
Pentadecanoic acid (PEA), an odd-chain fatty acid derived from diet by the gut microbiome, has garnered increasing attention for its systemic health-promoting properties. Its potential role in bladder Show more
Pentadecanoic acid (PEA), an odd-chain fatty acid derived from diet by the gut microbiome, has garnered increasing attention for its systemic health-promoting properties. Its potential role in bladder cancer (BC) occurrence and invasion, however, remains unclear. Large-scale cohorts' analyses were performed to assess the association between dietary PEA and BC occurrence and invasion. In vitro and in vivo experiments, including EJ and T24 BC cell assays and a BBN-induced mouse model, were conducted to experimentally assess the impact of PEA on BC. Serum proteomics, gut microbiome, and targeted fecal lipidomics analyses were employed to explore the underlying mechanisms. Dietary PEA was negatively associated with BC occurrence and invasion in cohort analyses. PEA suppressed EJ and T24 BC cell migration, invasion, and proliferation, while inhibiting BC development in a BBN-induced mouse model. In vivo serum proteomics identified differentially expressed lipid-related proteins (e.g., Apoe and Apob) following PEA treatment, implicating its modulation of lipid metabolism pathways. Considering the essential role of the gut-bladder axis, the gut microbiome analysis exhibited that PEA markedly altered bacteria (e.g., g_Alistipes) and fungi (e.g., o_Erysiphales, g_Teberdinia, and g_Gibberella), with concomitant lipid metabolism changes. Furthermore, targeted fecal lipidomics demonstrated the shifts in key lipids, such as phosphatidylethanolamines (PE) involved in essential lipid clusters, suggesting regulation by gut microbiome linked to BC development. Collectively, our findings demonstrate that PEA mitigates BC by reshaping the gut microbiome and modulating lipid metabolism, providing new insights into its molecular and therapeutic potential. Show less
📄 PDF DOI: 10.1186/s12916-025-04554-5
APOB
Fang Cheng, Xinyu Niu, Yaoling Wang +3 more · 2025 · Diabetology & metabolic syndrome · BioMed Central · added 2026-04-24
The Glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR) are well-established drug targets for the treatment of diabetes and obesity. Studies Show more
The Glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR) are well-established drug targets for the treatment of diabetes and obesity. Studies have linked GLP-1R agonist to cardiometabolic diseases (CMDs), while the therapeutic potential of the GIPR agonist remains a topic of debate. Using genetic variants as instrumental variables, we performed a two-sample Mendelian randomization (MR) analysis to investigate causal relationships between genetically proxied GIPR agonist and 23 CMD outcomes, and a two-step mediation analysis to identify mediating inflammatory biomarkers. The inverse variance weighted (IVW) method served as the primary analytical approach, supplemented by sensitivity analyses to validate robustness. The genetic mimicry of GIPR enhancement showed significant protective associations with 14 CMDs. Mediation analysis revealed that Fms-related tyrosine kinase 3 ligand (Flt3L) partially mediated the effects of GIPR agonist on angina (OR 0.997 [0.995-0.999], P = 0.0048) and myocardial infarction(MI) (OR 0.998 [0.996-0.999], P = 0.0077), accounting for 15.49% and 16.71% of the total risk reduction, respectively. Our study revealed that GIPR agonist lowers the risk of 14 CMDs. Flt3L is pinpointed as a key mediating factor in reducing angina and MI risk, suggesting a new therapeutic avenue. Show less
📄 PDF DOI: 10.1186/s13098-025-01744-2
GIPR
Fei Lu, Lan Li, Li Wang +6 more · 2025 · Discover oncology · Springer · added 2026-04-24
This study aims to comprehensively analyze the genetic characteristics and prognostic value of stemness- and epithelial-mesenchymal transformation (EMT)-related gene signatures in lung adenocarcinoma Show more
This study aims to comprehensively analyze the genetic characteristics and prognostic value of stemness- and epithelial-mesenchymal transformation (EMT)-related gene signatures in lung adenocarcinoma (LUAD). The RNA-sequencing transcriptome profiling data and corresponding clinical information of LUAD were procured from TCGA-LUAD and GEO datasets. After screening, we first obtained 1488 stemness- and EMT-related genes. Then 304 hub genes were obtained via WGCNA, of which 52 genes were established to be prognosis-related hub genes. Thereafter, a prognostic model containing 11 genes (ANGPTL4, CCL20, ENO1, FGF2, LGR4, PIM2, S100P, SATB2, SHOX2, ZNF322, and CFTR) was constructed. We demonstrated that a higher risk score was an independent negative prognostic factor in LUAD patients. A nomogram was further constructed to better predict the survival of LUAD patients. More importantly, we found that the low-risk group has a more favorable anti-tumor immune microenvironment and may benefit more from immunotherapy. We finally noticed that the high-risk group was more sensitive to most drugs including drugs commonly used to treat LUAD patients. In conclusion, this study has summarized the alterations and prognostic role of stemness- and EMT-related gene signatures in LUAD and constructed a prognostic model to accurately and stably predict survival and guide individualized treatment decisions. Show less
📄 PDF DOI: 10.1007/s12672-025-02866-9
ANGPTL4
Haotian Chen, Zhengye Liu, Hanze Du +7 more · 2025 · BMJ open gastroenterology · added 2026-04-24
Gallstone disease (GD) is a common gastrointestinal disorder with a significant genetic component. Despite known risk factors, the genetic basis of GD remains incompletely understood. We aimed to iden Show more
Gallstone disease (GD) is a common gastrointestinal disorder with a significant genetic component. Despite known risk factors, the genetic basis of GD remains incompletely understood. We aimed to identify novel genetic loci associated with GD, explore their clinical implications and investigate their therapeutic potential. We conducted a genome-wide association study from the UK Biobank followed by a meta-analysis, integrating summary statistics from the FinnGen R11, with further replication from Biobank Japan. Using systematic bioinformatic approaches, we performed gene prioritisation, colocalisation analysis, transcriptome-wide association study, Mendelian randomisations, cross-trait genetic correlations, phenome-wide association study, clinical investigations and gene-environment interactions by leveraging data from the FinnGen, Genotype-Tissue Expression project and Liver Cell Atlas single-cell transcriptomics data set. Our study highlighted novel susceptibility loci near candidate genes (ie, This study provides new insights into the genetic basis of GD and highlights the role of hepatocytes in GD pathogenesis. These findings have implications for the personalised prevention strategies and new therapeutic interventions in individuals predisposed to GD. Show less
📄 PDF DOI: 10.1136/bmjgast-2025-001976
FADS1
Nolan Priedigkeit, Beth Harrison, Robert Shue +27 more · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research · added 2026-04-24
Inflammatory breast cancer (IBC) is a rare and clinically distinct form of breast cancer associated with poor outcomes. The biological mechanisms driving IBC remain poorly understood, partly due to li Show more
Inflammatory breast cancer (IBC) is a rare and clinically distinct form of breast cancer associated with poor outcomes. The biological mechanisms driving IBC remain poorly understood, partly due to limited large-scale genomic studies that directly compare IBC with non-IBC cases. We conducted a retrospective analysis of 140 patients with IBC (68 primary tumors and 72 metastatic tumors) and 2,317 patients with non-IBC (700 primary tumors, 65 local recurrences, and 1,552 metastases). We compared clinicopathologic features, single-nucleotide variants, copy-number variants, tumor mutational burden, and exploratory survival outcomes between IBC and non-IBC tumors. The most frequent somatic alterations in IBC were detected in TP53 (72%), ERBB2 (32%), PIK3CA (24%), CCND1 (12%), MYC (9%), FGFR1 (8%), and GATA3 (8%). Multivariate logistic regression revealed a significant enrichment of TP53 single-nucleotide variants in IBC, particularly in HER2+ and hormone receptor-positive disease. Tumor mutational burden did not differ between IBC and non-IBC cases. In HER2+ disease, a pathway analysis revealed an enrichment of NOTCH pathway alterations. TP53, CCND1, and RB1 alterations were associated with poor outcomes in IBC. This study provides a comprehensive resource of somatic alterations in a large cohort of patients with metastatic IBC and non-IBC, highlighting genomic features associated with worse outcomes. Our findings reveal a significant enrichment of TP53 mutations, reinforcing its critical role in IBC pathogenesis. Few other distinct differences in IBC were observed, suggesting further investigations-beyond bulk sequencing of the somatic genome-are required to better understand the biology driving this aggressive disease. Show less
📄 PDF DOI: 10.1158/1078-0432.CCR-24-2081
FGFR1
Kang-Fu Yin, Ting Chen, Xiao-Jing Gu +8 more · 2025 · Molecular neurobiology · Springer · added 2026-04-24
Current research lacks comprehensive investigations into the potential causal link between mitochondrial-related genes and the risk of neurodegenerative diseases (NDDs). We aimed to identify potential Show more
Current research lacks comprehensive investigations into the potential causal link between mitochondrial-related genes and the risk of neurodegenerative diseases (NDDs). We aimed to identify potential causative genes for five NDDs through an examination of mitochondrial-related gene expression levels. Through the integration of summary statistics from expression quantitative trait loci (eQTL) datasets (human blood and brain tissue), mitochondrial DNA copy number (mtDNA-CN), and genome-wide association studies (GWAS) datasets of five NDDs from European ancestry, we conducted a Mendelian randomization (MR) analysis to explore the potential causal relationship between mitochondrial-related genes and Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Lewy body dementia (LBD). Sensitivity analysis and Bayesian colocalization were employed to validate this causal relationship. Through MR analysis, we have identified potential causal relationships between 12 mitochondria-related genes and AD, PD, ALS, and FTD overlapping with motor neuron disease (FTD_MND) in human blood or brain tissue. Bayesian colocalization analysis further confirms 9 causal genes, including NDUFS2, EARS2, and MRPL41 for AD; NDUFAF2, MALSU1, and METTL8 for PD; MYO19 and MRM1 for ALS; and FASTKD1 for FTD_MND. Importantly, in both human blood and brain tissue, NDUFS2 exhibits a significant pathogenic effect on AD, while NDUFAF2 demonstrates a robust protective effect on PD. Additionally, the mtDNA-CN plays a protected role in LBD (OR = 0.62, p = 0.031). This study presents evidence establishing a causal relationship between mitochondrial dysfunction and NDDs. Furthermore, the identified candidate genes may serve as potential targets for drug development aimed at preventing NDDs. Show less
no PDF DOI: 10.1007/s12035-024-04528-3
MYO19
Hongxin Cheng, Qing Zhang, Wen Zhong +6 more · 2025 · Signal transduction and targeted therapy · Nature · added 2026-04-24
Atherosclerosis serves as the core pathological basis of cardiovascular, cerebrovascular, and peripheral arterial diseases, posing a serious threat to human health. However, current mainstream treatme Show more
Atherosclerosis serves as the core pathological basis of cardiovascular, cerebrovascular, and peripheral arterial diseases, posing a serious threat to human health. However, current mainstream treatments such as statin drugs and stent implantation are associated with significant side effects or limited efficacy, highlighting the urgent need for new therapeutic strategies. Pulsed electromagnetic fields (PEMFs), due to their noninvasive nature and anti-inflammatory properties, show potential in the treatment of atherosclerosis. This study utilized ApoE-/- mice, ApoE-/-NLRP3-/- knockout mice, human umbilical vein endothelial cells (HUVECs), human aortic endothelial cells (HAECs), and human plasma samples for experiments, revealing significant endothelial cell (EC) inflammation and pyroptosis during the progression of atherosclerosis. PEMFs were found to effectively inhibit the activation of the NLRP3 inflammasome, reduce plaque formation, and delay the progression of atherosclerosis. Proteomic analysis of plasma from atherosclerosis patients further indicated elevated expression levels of proteins related to inflammation and pyroptosis, with particularly notable changes in membrane proteins. Mechanistic studies demonstrated that PEMFs improve mitochondrial dysfunction in ECs by regulating membrane tension and the mechanosensitive tension-mediated transient receptor potential vanilloid 4 (TRPV4) channels, thereby reducing pyroptosis. This discovery not only reveals a novel mechanobiological pathway but also provides a solid theoretical foundation for the development of PEMF-based therapies for atherosclerosis. Schematic diagram of the mechanism by which PEMFs treat atherosclerosis (created in BioRender). Wei, B. (2025) https://BioRender.com/undefined ). Show less
📄 PDF DOI: 10.1038/s41392-025-02479-2
APOE
Ting He, Jinbo Zhao, Ling Hou +2 more · 2025 · International journal of general medicine · added 2026-04-24
Coronary heart disease (CHD) has a significant co-morbid association with chronic kidney disease (CKD), but identification tools for the risk of concomitant CKD in patients with CHD are still lacking. Show more
Coronary heart disease (CHD) has a significant co-morbid association with chronic kidney disease (CKD), but identification tools for the risk of concomitant CKD in patients with CHD are still lacking. The purpose of this research was to construct machine learning (ML) models for identifying undetected CKD in CHD patients. 1786 CHD patients undergoing coronary intervention were retrospectively included. Lasso regression and multifactor logistic regression were used to screen feature variables. Five ML models, ie, logistic regression (LR), support vector machine (SVM), random forest (RF), gradient boosting machine (GBM), and extreme gradient boosting (XGBoost), were constructed. Participants were divided into the training set and validation set in a 7:3 ratio. The evaluation metrics included the area under the curve, calibration curve, and decision curve. Totally, 1786 CHD patients were enrolled and split into training (70%) and validation (30%) sets. The prevalence of CKD was 21.8% (390/1786). Multivariate logistic regression analysis showed that men, advanced age, hypertension, diabetes mellitus, history of atrial fibrillation (AF), high Gensini, low hemoglobin, low plateletcrit (PCT), high triglycerides (TG), high lipoprotein(a) (Lp(a)), hyperkalemia, high uric acid to albumin ratio (UAR), high systemic inflammation response index (SIRI), low lymphocyte to monocyte ratio (LMR), and high apolipoprotein B to apolipoprotein A1 (ApoB/ApoA1) ratio were the key clinical and laboratory test indicators of CKD. The XGBoost model performed optimally in the validation set (AUC=0.909, 95% CI 0.881 -0.937). SHapley Additive explanation analysis identified UAR, hypertension, Gensini score, age, and SIRI as the top 5 key features. The XGBoost model constructed on routine clinical data was effective in identifying CKD risk in CHD patients, with UAR as a novel strong predictor. Decision curve analysis confirmed the clinical utility of the model, indicating that it may be used to guide decisions for enhanced monitoring and early intervention over a wide range of risk thresholds. Show less
📄 PDF DOI: 10.2147/IJGM.S558568
APOB
Xiaoqiang Wei, Lihui Wang, Haiwang Zhang +6 more · 2025 · Frontiers in microbiology · Frontiers · added 2026-04-24
Forage scarcity during the cold season poses a major challenge to livestock farming on the Qinghai-Tibet Plateau. Jerusalem artichoke (
📄 PDF DOI: 10.3389/fmicb.2025.1699658
LPL
Xueying Fan, Baoting Li, Fan Zhang +4 more · 2025 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Wiley · added 2026-04-24
Liver and lung are the most common metastatic sites in colorectal cancer (CRC), where the tumor microenvironment (TME) plays a crucial role in the progression and metastasis of CRC. Understanding the Show more
Liver and lung are the most common metastatic sites in colorectal cancer (CRC), where the tumor microenvironment (TME) plays a crucial role in the progression and metastasis of CRC. Understanding the interactions between various types of cells in the TME can suggest innovative therapeutic strategies. Using single-cell RNA sequencing (scRNA-Seq) and clinical samples, fibroblast growth factor-19 (FGF19, rodent FGF15) is found to mediate a significant interaction between CRC cells and cancer-associated fibroblasts (CAFs), activating the hepatic stellate cells (HSCs)-to-CAFs differentiation. In various CRC metastatic mouse models, it is shown that FGF15 has a more pronounced effect on liver metastasis compared to pulmonary metastasis. More importantly, the differentially expressed genes (DEGs) are also identified from the RNA-Seq dataset upon the activation of HSCs by FGF19 and compared the DEGs in matched primary and metastatic mRNA samples from patients with CRC liver metastasis (CRCLM), it is found that the ANGPTL4 gene is significantly associated with HSCs activation. Different mouse models also demonstrated the impact of the FGF19/ANGPTL4 axis on the severity of CRCLM. Importantly, disruption of this axis significantly inhibits CRCLM in vivo. This study is among the first to demonstrate the impact of the FGF19/ANGPTL4 axis on CRCLM, offering a novel therapeutic strategy. Show less
📄 PDF DOI: 10.1002/advs.202413525
ANGPTL4
Chongyang Cai, Leipeng Li, Xiaohuan Lv +12 more · 2025 · Nature communications · Nature · added 2026-04-24
Lanthanides-doped luminescent materials have gathered considerable attention due to their application potential in stress sensing, lighting and display, anti-counterfeiting technology and so forth. Ho Show more
Lanthanides-doped luminescent materials have gathered considerable attention due to their application potential in stress sensing, lighting and display, anti-counterfeiting technology and so forth. However, existing materials mainly cover the 380-1540 nm range, with slight extension to the UV region, impeding their applications in solar-blind imaging, background-free tracking, concealed communication, etc. To address this challenge, here we propose guidelines for far-UVC (200-230 nm) optical design. Accordingly, we achieve multi-stimulated far-UVC luminescence at ~222 nm in Pr Show less
📄 PDF DOI: 10.1038/s41467-025-61522-6
LPL
Xiaokun Li, Zhiheng Rao, Wenhao Hu +2 more · 2025 · Obesity reviews : an official journal of the International Association for the Study of Obesity · Blackwell Publishing · added 2026-04-24
Metabolic dysfunction-associated steatohepatitis (MASH) is a condition characterized by hepatosteatosis, inflammation, and tissue damage, with steatosis as the initial stage, which involves chronic, e Show more
Metabolic dysfunction-associated steatohepatitis (MASH) is a condition characterized by hepatosteatosis, inflammation, and tissue damage, with steatosis as the initial stage, which involves chronic, excess deposition of lipids in hepatic lipid droplets. Despite the growing prevalence and serious risks it poses, including liver decompensation, the need for transplantation, and increased patient mortality, MASH currently faces no approved pharmacotherapy. Several promising treatment candidates have emerged from recent clinical trials, including analogs of FGF21 and agonists of the associated FGFR1-KLB complex. These agents were well-tolerated in trials and have demonstrated significant improvements in both histological and biochemical markers of liver fat content, inflammation, injury, and fibrosis in patients with MASH. Endocrine FGF21 plays a vital role in maintaining homeostasis of lipid, glucose, and energy metabolism. It achieves this through pathways that target lipids or lipid droplets in adipocytes and hepatocytes. Mechanistically, pharmacological FGF21 acts as a potent catabolic factor to promote lipid or lipid droplet lipolysis, fatty acid oxidation, mitochondrial catabolic flux, and heat-dissipating energy expenditure, leading to effective clearance of hepatic and systemic gluco-lipotoxicity and inflammatory stress, thereby preventing obesity, diabetes, and MASH pathologies. In this review, we aim to provide an update on the outcomes of clinical trials for several FGF21 mimetics. We compare these outcomes with preclinical studies and offer a lipid-centric perspective on the mechanisms underlying the clinical benefits of these agents for MASH. Show less
no PDF DOI: 10.1111/obr.13861
FGFR1
Yanting Zhang, Fei Cheng, Lixia Li · 2025 · Medicine · added 2026-04-24
Prostate cancer is epithelial malignant prostate hyperplasia caused by a tumor. We found prostate cancer GSE141551 and GSE200879 profiles from gene expression omnibus database, followed by differentia Show more
Prostate cancer is epithelial malignant prostate hyperplasia caused by a tumor. We found prostate cancer GSE141551 and GSE200879 profiles from gene expression omnibus database, followed by differentially expressed genes (DEGs) analysis, weighted gene co-expression network analysis, protein-protein interaction analysis, gene function enrichment analysis, and comparative toxicology database analysis. Finally, the gene expression heat map was drawn, and miRNA information regulating core DEGs was retrieved. A total of 1151 DEGs were found, most of them focusing on systematic development, cell development, cell differentiation, regulation of multicellular biological processes, anatomical morphogenesis, MAPK signaling pathway, proteoglycans in cancer, fluid shear stress, and atherosclerosis. The core genes (MYL9, TAGLN, SMTN, CNN1, MYH11, MYLK, MYOCD, ACTC1, LMOD1, and TPM2) obtained in end are all lowly expressed in prostate cancer samples and are associated with hypertension, tumor metastasis, prostate tumors, and tumor aggressiveness. LMOD1 and SMTN are lowly expressed in prostate cancer and may be used as markers in prostate cancer nursing. Show less
📄 PDF DOI: 10.1097/MD.0000000000041357
LMOD1
Ruijun Sun, Yuchi Zhang, Jingying Xu +7 more · 2025 · Archiv der Pharmazie · Wiley · added 2026-04-24
Acetylcholinesterase (AChE) inhibitors are crucial for the symptomatic management of Alzheimer's disease (AD), with natural products-particularly botanical sources like Yellow Gastrodia elata (YGE)-se Show more
Acetylcholinesterase (AChE) inhibitors are crucial for the symptomatic management of Alzheimer's disease (AD), with natural products-particularly botanical sources like Yellow Gastrodia elata (YGE)-serving as promising reservoirs of such inhibitors. Nevertheless, comprehensive screening and mechanistic characterization of their inhibitory potential remain limited. This study sought to identify potent AChE inhibitors from YGE, investigate their mechanisms of action, and assess their therapeutic prospects for AD. Methodologically, an integrated approach was employed, combining ultrafiltration-liquid chromatography (UF-LC) for rapid inhibitor screening, molecular docking and dynamics simulations for mechanistic insight, two-stage high-speed countercurrent chromatography for compound isolation, enzyme kinetics to delineate inhibition modalities, and network pharmacology to uncover relevant AD-related targets. The findings identified seven active constituents with notable AChE inhibition, among which parishins A and G were obtained at high purity (98.26% and 97.26%, respectively) and exhibited mixed-type inhibition with low IC Show less
no PDF DOI: 10.1002/ardp.70174
BACE1
Beibei Bie, Hong Bai, Yingnan Li +2 more · 2025 · IUBMB life · Wiley · added 2026-04-24
G-patch domain-containing protein 2 (GPATCH2), a member of the G-patch domain-containing family, has been implicated in tumor cell growth, but the link between GPATCH2 and hepatocellular carcinoma (HC Show more
G-patch domain-containing protein 2 (GPATCH2), a member of the G-patch domain-containing family, has been implicated in tumor cell growth, but the link between GPATCH2 and hepatocellular carcinoma (HCC) remains uncertain. In the current study, comprehensive bioinformatics analysis revealed that GPATCH2 was markedly upregulated in HCC and positively correlated with aggressive clinicopathological features, including histologic grade, AFP, albumin level, and adjacent hepatic tissue inflammation, as well as miserable outcomes in HCC. GPATCH2 also has certain diagnostic value for HCC, histologic grade, and 1-, 3-, and 5-year survival outcomes. Functionally, loss-of-function experiments disclosed that silencing GPATCH2 suppressed HCC cell proliferation, migration, invasion, and xenograft tumor growth in the subcutaneous mouse model. Silencing GPATCH2 also resulted in an increase in the expression level of CDH1, while causing a decrease in the expression levels of FN1, TWIST1, SNAI1, and SNAI2. Rescue experiments further confirmed SNAI2 as a critical downstream effector mediating GPATCH2-driven oncogenic activity in HCC. Mechanistically, GPATCH2 was uncovered to be transcriptionally activated by the transcription factor Yin Yang 1 (YY1), and can mediate the role of YY1 in promoting HCC progression and elevating SNAI2 expression. Taken together, GPATCH2 is a YY1-regulated oncogenic driver that promotes HCC advancement through SNAI2, highlighting its potential as a diagnostic, prognostic, and therapeutic target for HCC. Show less
no PDF DOI: 10.1002/iub.70070
SNAI1
Xiangyang Li, Xiaomin Zhang, Nina Wei +2 more · 2025 · Frontiers in pharmacology · Frontiers · added 2026-04-24
Hyperlipidemia and its associated hepatic steatosis pose significant global health burdens, necessitating novel therapeutic strategies. High-fat diet (HFD)-fed C57BL/6 mice received TAC (2.5, 5.0, 10. Show more
Hyperlipidemia and its associated hepatic steatosis pose significant global health burdens, necessitating novel therapeutic strategies. High-fat diet (HFD)-fed C57BL/6 mice received TAC (2.5, 5.0, 10.0 g/L) or simvastatin for 2 weeks. Metabolic parameters, serum lipid profiles, hepatic function markers, and histopathology were systematically analyzed. Molecular pathways were interrogated through qPCR, Western blot, and pharmacological inhibition of AMPK (Compound C) and PPARα (GW6471). TAC treatment demonstrated significant dose-dependent improvements across multiple parameters. Compared to HFD controls, TAC reduced body weight by 21.3% and liver index by 18.7%, while lowering fasting blood glucose levels by 32.4%. Serum analyses showed substantial reductions in total cholesterol (46.2%), triglycerides (38.5%), and LDL-cholesterol (52.1%), accompanied by a 29.8% increase in HDL-cholesterol. Hepatic function improved markedly, with ALT and AST levels decreasing by 57.3% and 49.6% respectively. Histopathological examination revealed a 68.4% reduction in hepatic lipid accumulation. At the molecular level, TAC treatment resulted in a 2.7-fold increase in AMPK phosphorylation while significantly reducing HMGCR expression by 63.1% and nuclear SREBP-1c levels by 71.5%. Concurrently, TAC upregulated PPARα and LXRα expression by 3.1-fold and 2.4-fold respectively, leading to enhanced expression of lipolytic enzymes LPL and HL by 2.8-fold and 2.1-fold. These beneficial effects were completely abolished by co-treatment with pathway-specific inhibitors. TAC ameliorates hyperlipidemia and hepatic steatosis through dual modulation of AMPK/SREBP-1c-mediated lipid synthesis and PPARα/LXRα-driven lipolysis, presenting a multifaceted therapeutic approach for metabolic disorders. Show less
📄 PDF DOI: 10.3389/fphar.2025.1662325
LPL
Qiusheng Li, Changjing Wang, Guiying Wang · 2025 · Scientific reports · Nature · added 2026-04-24
COL4A1, a key component of the basement membrane, has been increasingly implicated in tumor progression, yet its role in colon cancer remains incompletely understood. In this study, we conducted a com Show more
COL4A1, a key component of the basement membrane, has been increasingly implicated in tumor progression, yet its role in colon cancer remains incompletely understood. In this study, we conducted a comprehensive integrative analysis using transcriptomic data from the TCGA-COAD cohort, combined with functional validation in colon cancer cell lines. Gene set enrichment analysis (GSEA) revealed that high COL4A1 expression was associated with oncogenic pathways including epithelial-mesenchymal transition (EMT), KRAS signaling, and inflammatory responses. Immune infiltration analysis indicated that COL4A1 expression negatively correlated with CD8 Show less
no PDF DOI: 10.1038/s41598-025-17230-8
SNAI1
Chunqing Li, Longting Wu, Fang Hu +2 more · 2025 · Ecology and evolution · Wiley · added 2026-04-24
Understanding the adaptive evolution of brain function in extreme environments remains a central challenge in evolutionary biology. This study investigates the molecular mechanisms underlying cave ada Show more
Understanding the adaptive evolution of brain function in extreme environments remains a central challenge in evolutionary biology. This study investigates the molecular mechanisms underlying cave adaptation by comparing brain transcriptomes of sympatric cave-dwelling ( Show less
📄 PDF DOI: 10.1002/ece3.72652
ADCY3
Rongqing Li, Zikai Zhang, Xin Zhang +6 more · 2025 · BMC neurology · BioMed Central · added 2026-04-24
Symptom burden in primary brain tumor patients varies, emphasizing the need for comprehensive understanding to improve patient care. This study aims to identify distinct symptom clusters among brain t Show more
Symptom burden in primary brain tumor patients varies, emphasizing the need for comprehensive understanding to improve patient care. This study aims to identify distinct symptom clusters among brain tumor patients in Shanghai, China, using Latent Profile Analysis (LPA) to guide personalized diagnosis, treatment, and supportive care. A longitudinal study was conducted among 161 patients with primary brain tumors in Shanghai. Participants completed the MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) at three intervals: the day of admission (T1), three days after surgery (T2), and two weeks after surgery (T3). Latent Profile Analysis (LPA) was used to identify subgroups with unique symptom patterns. Six distinct subgroups were identified (entropy = 0.964), ranging from low-burden to persistently severe patterns. Subgroup membership was partially associated with age, tumor grade, and diagnosis. These subgroups were: transient postoperative burden group, stable symptom with cognitive emergence group, distress-predominant, low burden group, elderly-high grade, persistently severe group, nausea-dominant recovery group, and distress-plus-nausea, younger urban group. Our findings reveal substantial heterogeneity in perioperative symptom experiences among brain tumor patients. Identifying subgroups with high and persistent symptom burden may help clinicians target interventions such as enhanced education, proactive monitoring, rehabilitation, psychological support, and antiemetic management. This subgroup-based approach may improve quality of life, reduce morbidity, and guide precision supportive care in neuro-oncology. Show less
📄 PDF DOI: 10.1186/s12883-025-04595-6
LPA
Maozhong Yao, Keyan Zhong, Xinbin Zheng +4 more · 2025 · Journal of cellular and molecular medicine · Blackwell Publishing · added 2026-04-24
Endothelial-to-mesenchymal transition (EndMT) induced by dysfunctional pulmonary artery endothelial cells (PAECs) is regarded as an initiating and pivotal factor in pulmonary hypertension (PH). This s Show more
Endothelial-to-mesenchymal transition (EndMT) induced by dysfunctional pulmonary artery endothelial cells (PAECs) is regarded as an initiating and pivotal factor in pulmonary hypertension (PH). This study focuses on identifying a novel therapeutic target for regulating EndMT in PH. A comprehensive analysis of 2 hypoxic PAECs datasets yielded 310 overlapping upregulated and 229 downregulated differentially expressed genes (DEGs). These upregulated DEGs were primarily enriched in HIF-1 signalling pathway and glycolysis/gluconeogenesis, while downregulated only in spliceosome, as indicated by KEGG. Through PPI network analysis and the application of MCC algorithms, 5 hub genes were identified among these upregulated DEGs: GAPDH, LDHA, ALDOA, PFKL, and PFKP. Their enrichment in the 2 aforementioned pathways was confirmed by cross-pathway DEGs analysis and ClueGo. Among the hub genes, LDHA was chosen as the key gene based upon expression and correlation analysis of the validation set from PH patients. Subsequent GSEA also revealed the enrichment of LDHA in these 2 pathways. Additionally, the increased expression of LDHA protein in tissues and cells was confirmed, and the elevated enzymatic activity of LDHA in clinical serum samples was also verified. From 2 online databases, 4 LDHA inhibitors were filtered out, and the stable binding between the inhibitors and the LDHA protein was confirmed through molecular docking and molecular dynamics simulation. Finally, the experimental results indicated that one of the inhibitors FX11 reversed EndMT by inhibiting the lactate-SNAI1 axis, thereby alleviating hypoxia-induced PH. The potential of LDHA as a therapeutic target for PH by modulating EndMT was proposed in this study. Show less
no PDF DOI: 10.1111/jcmm.70692
SNAI1
Hualing Li, Junjie Wei, Zhiyi Zheng +6 more · 2025 · Free radical biology & medicine · Elsevier · added 2026-04-24
The established body of knowledge attests to the pivotal influence of ANGPTL4 on lipid metabolism and vascular biology. Nevertheless, its potential implication in neurodegenerative disease remains to Show more
The established body of knowledge attests to the pivotal influence of ANGPTL4 on lipid metabolism and vascular biology. Nevertheless, its potential implication in neurodegenerative disease remains to be fully characterized. The present investigation delves into the involvement of ANGPTL4 in the pathological progression of PD, both in vitro and in vivo. PD models were induced by intraperitoneal administration of MPTP and LPS in WT and ANGPTL4 The observations unveiled that ANGPTL4 deficiency exacerbated behavioral aberrations, intensified dopaminergic neuron loss, and stimulated microglial activation along with p21-dependent senescence. There was an elevation in the expression of proinflammatory cytokines in the PD model. Furthermore, the administration of rANGPTL4 protein reversed the observed phenotypes in ANGPTL4 Our findings posit a salutary role for ANGPTL4 in counteracting PD, rendering it a prospective therapeutic target for the development of innovative drugs aimed at treating neuroinflammation-associated neurological diseases, including PD. Show less
no PDF DOI: 10.1016/j.freeradbiomed.2024.12.009
ANGPTL4
William Stewart, Bin Hu, Fengqiao Li +6 more · 2025 · Journal of controlled release : official journal of the Controlled Release Society · Elsevier · added 2026-04-24
Obesity, a widespread global health issue affecting millions, is characterized by excess fat deposition and metabolic dysfunction, significantly elevating the risk of comorbidities like type 2 diabete Show more
Obesity, a widespread global health issue affecting millions, is characterized by excess fat deposition and metabolic dysfunction, significantly elevating the risk of comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers, all of which contribute to rising rates of preventable morbidity and mortality. Current approaches to obesity, including lifestyle modifications, and pharmacotherapy, often face limitations such as poor long-term adherence, side effects, and insufficient targeting of the complex, multifactorial pathways underlying the disease. Herein we report a dual, RNA-mediated combinatorial approach using targeting lipid nanoparticles (LNP) for the treatment of obesity. LNPs were co-encapsulated with mRNA encoding Interleukin-27 (mIL-27) to coactivate PGC-1α, PPARα, and UCP-1, thereby promoting adipocyte differentiation and enhancing adaptive thermogenesis within adipocytes, and siRNA targeting Dipeptidyl peptidase-4 (siDPP-4) to silence the primary inhibitory enzyme of GLP-1, and GIP within the incretin system, effectively restoring glucose homeostasis. Following post translational silencing of DPP-4 and upregulation of IL-27 in a diet-induced obesity (DIO) mice model, increased expression of thermogenic biomarkers PGC-1α, PPARα, and UCP-1 was observed at the molecular, protein, and tissue level, and insulin sensitivity was restored. Importantly, this gene modulation led to a 21.1 % reduction of bodyweight after treatment in the DIO model. These findings demonstrate for the first time a dual RNA-mediated combinatorial approach, leveraging liver targeting LNP delivery with synergistic effects from incretin system regulation and induction of adipocyte differentiation and thermogenesis after codelivery of siDPP-4 and mIL-27. This innovative strategy provides a promising alternate framework for addressing obesity and its associated metabolic dysfunction. Show less
no PDF DOI: 10.1016/j.jconrel.2025.113857
IL27